购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Refametinib

Rating icon 很棒
Refametinib
产品编号 T6636Cas号 923032-37-5
别名 瑞法替尼//瑞美替尼, RDEA119, BAY 86-97661, BAY 869766

Refametinib (RDEA119) 是可口服的、非 ATP 竞争和选择性的 MEK1/MEK2变构抑制剂,IC50分别为 19 和 47 nM。

Refametinib
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

Refametinib

Rating icon 很棒
Refametinib
纯度: 100%
产品编号 T6636 别名 瑞法替尼//瑞美替尼, RDEA119, BAY 86-97661, BAY 869766Cas号 923032-37-5

Refametinib (RDEA119) 是可口服的、非 ATP 竞争和选择性的 MEK1/MEK2变构抑制剂,IC50分别为 19 和 47 nM。

规格价格库存数量
1 mg
¥ 263
现货
2 mg
¥ 375
现货
5 mg
¥ 598
现货
10 mg
¥ 923
现货
25 mg
¥ 1,530
现货
50 mg
¥ 2,260
现货
100 mg
¥ 3,920
现货
1 mL x 10 mM (in DMSO)
¥ 777
现货
大包装 & 定制
加入购物车
该分子属于定制产品。TargetMol拥有优秀的合成团队,经验和能力,可以为您提供高性价比的产品。但由于客观因素,研发中会存在小概率合成不成功的情况,还请理解,如您有任何问题,欢迎咨询,我们将竭诚为您服务。
实验操作小课堂
常见问题解答
如果低于说明书给出的最高溶解度情况下,产品仍未溶解怎么办?
建议您使用一些辅助溶解方法,如水浴加热至 45℃ 或用超声震荡,加速粉末溶解。
抑制剂产品应如何储存?
粉末储存在 -20℃,可以存 3 年以上。 母液一般储存于 -80℃,可以存 1 年以上,建议多分装几管,避免反复冻融。 常用的存于 4℃,可放一周以上。
细胞实验中需要加多少抑制剂?
通常建议您参考同模型实验发表的文献报道;除参考文献报道以外,还需要通过预实验做“剂量-效应曲线”确定最佳作用浓度(浓度梯度);通过“时间-效应曲线”确定最佳孵育时间(处理时间梯度)。另外,抑制剂的使用量受多种因素影响,包括抑制对象的可接触性、细胞通透性、孵育时间、细胞种类等等。我们建议通过检索文献确定使用抑制剂的起始浓度。 如果有报道的 Ki 值或 IC50 值,可以采用其 5-10 倍的量开始尝试以达到抑制酶活性的最佳效果。 如果抑制剂的 Ki 值或 IC50 值未知,则需要在更广泛的范围尝试抑制剂的使用浓度,并采用 Michaelis-Menten 动力学计算 Ki 值。 一般设立溶解抑制剂时所采用的溶剂作为对照,以排除溶剂的非特异性影响。
产品溶解需要超声吗?如果没有超声仪怎么办?
超声可以加快粉末的溶解速度,如果您的化合物溶解不了,建议您尝试超声。如果您没有超声仪,建议您选择较低母液浓度,或者较少粉末量,尝试溶解。
抑制剂能否用于动物实验?
可以的,我们的抑制剂都可以用于动物/体内实验。但有些化合物还没有用于动物实验的文献,这种情况下,建议您先做预实验,确保研究的可行性。
查看更多

"Refametinib"的相关化合物库

选择批次:
纯度:99.84%
ee:97.95%
联系我们获取更多批次信息

产品介绍

生物活性
产品描述
Refametinib (RDEA119) (RDEA119, Bay 86-9766) is an effective, ATP non-competitive and specific inhibitor of MEK1/2 (IC50: 19/47 nM).
靶点活性
MEK2:47 nM, MEK1:19 nM
体外活性
RDEA119 is selectively bound directly to an allosteric pocket in the MEK1/2 enzymes, and highly efficacious at inhibiting cell proliferation in several tumor cell lines, including A375, SK-MEI-28, Colo205, HT-29 and BxPC3. RDEA119 inhibits anchorage-dependent growth of human cancer cell lines harboring the gain-of-function V600E BRAF mutant with GI50 values ranging from 67 to 89 nM. Under anchorage-independent conditions, GI50 values for all cell lines tested are similar (40-84 nM). RDEA119 shows a tissue selectivity that reduces its potential for central nervous system–related side effects. [1] RDEA119 potently inhibits the proliferation of the 4 cell lines that harbored BRAF mutation but has no or modest effects on the other 4 cells that harbored wild-type BRAF (IC50 of 0.034-0.217 μM vs. 1.413-34.120 μM). This inhibitory effect of RDEA119 in selected cell lines OCUT1 (BRAF V600E(+), PIK3CA H1047R(+)) and SW1376 (BRAF V600E(+)) is enhanced by combination with the mTOR inhibitor, temsirolimus. RDEA119 and temsirolimus also show synergistic effects on autophagic death of OCUT1 and KAT18 cells selectively tested. [2]
体内活性
Oral administration of RDEA119 at 50 mg/kg on a once daily x 14 schedule leads to a 68% tumor growth inhibition (TGI) in human melanoma A375 tumor model. Oral administration of RDEA119 at 25 mg/kg on a once a once daily x 14 schedule leads to a 123% TGI in human colon carcinoma Colo205 tumor model (TGI > 100% occurs when the tumor shrinks below its starting volume). A dose of 25 mg/kg once daily x 14 produces 56% and 67% TGI for HT-29 and A431 tumors, respectively. [1]
激酶实验
MEK Kinase Assay: Kinase inactive murine ERK2 (mERK2) K52A/T183A is affinity purified from Escherichia coli expressed using the pET21a vector. MEK1 kinase activity is determined using mERK2 K52A T183A as the substrate. Recombinant MEK1 enzyme (5 nM) is first activated by 0.02 unit or 1.5 nM of RAF1 in the presence of 25 mM HEPES (pH 7.8), 1 mM MgCl2, 50 mM NaCl, 0.2 mM EDTA, and 50 μM ATP for 30 minutes at 25 °C. The reactions are initiated by adding 2 μM of mERK2K52A T183A and 2.5 μCi [γ-33P] ATP in a total volume of 20 μL. The MEK2 kinase activity is determined similarly except that activation by RAF1 is not needed and 11 nM of MEK2 enzyme (active) are used in the assays.Kinase profiling is performed by Invitrogen using their Select Screen Kinase Profiling Service. The Z'-LYTE biochemical assay is used. RDEA119 is assayed in quadruplicate at 10 μM against 205 kinases.
细胞实验
For anchorage-dependent growth inhibition experiments, cells are plated in white 384-well plates at 1,000/20 μL/well or white 96-well microplates at 4,000/100 μL/well. After 24-h incubation at 37 °C, 5% CO2, and 100% humidity, RDEA119 is incubated for 48 hours at 37 °C and assayed using CellTiter-Glo. For the 96-well anchorage-independent growth assay, wells of an "ultralow binding" plate (Corning) are filled with 60 μL of a 0.15% agarose solution in complete RPMI 1640. Then, 60 μL of complete RPMI 1640 containing 9,000 cells in 0.15% agarose are added per well. After 24 hour, 60 μL of a 3 × drug solution in agarose-free complete RPMI 1640 are added. After 7 d, 36 μL of 6 × 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 2H-tetrazolium, inner salt reagent are added per well. After 2 hours at 37 °C, absorbance at 490 nm is determined on the M5 plate reader. (Only for Reference)
别名瑞法替尼//瑞美替尼, RDEA119, BAY 86-97661, BAY 869766
化学信息
分子量572.34
分子式C19H20F3IN2O5S
CAS No.923032-37-5
SmilesS(NC1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1OC)(=O)(=O)C3(C[C@@H](CO)O)CC3
密度1.82 g/cm3 (Predicted)
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
Ethanol: 93 mg/mL (162.49 mM), Sonication is recommended.
DMSO: 93 mg/mL (162.49 mM), Sonication is recommended.
H2O: < 1 mg/mL (insoluble or slightly soluble)
溶液配制表
Ethanol/DMSO
1mg5mg10mg50mg
1 mM1.7472 mL8.7361 mL17.4721 mL87.3607 mL
5 mM0.3494 mL1.7472 mL3.4944 mL17.4721 mL
10 mM0.1747 mL0.8736 mL1.7472 mL8.7361 mL
20 mM0.0874 mL0.4368 mL0.8736 mL4.3680 mL
50 mM0.0349 mL0.1747 mL0.3494 mL1.7472 mL
100 mM0.0175 mL0.0874 mL0.1747 mL0.8736 mL

SCI 文献

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60%Saline/PBS/ddH2O, 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLSaline/PBS/ddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

参考文献

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy Refametinib | purchase Refametinib | Refametinib cost | order Refametinib | Refametinib chemical structure | Refametinib in vivo | Refametinib in vitro | Refametinib formula | Refametinib molecular weight